Ignite Creation Date:
2024-05-06 @ 9:15 AM
Last Modification Date:
2024-10-26 @ 12:12 PM
Study NCT ID:
NCT02940132
Status:
UNKNOWN
Last Update Posted:
2017-12-06
First Post:
2016-10-08
Brief Title:
A Study of SC10914 in Patients With Advanced Solid Tumors
Sponsor:
Jiangxi Qingfeng Pharmaceutical Co Ltd
Organization:
Jiangxi Qingfeng Pharmaceutical Co Ltd
Study Overview
Official Title:
Phase 1 Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of SC10914 in Patients With Advanced Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2016-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SC10914 is a potent selective PARP-1 and PARP-2 inhibitor This study aims to determine the safety tolerability pharmacokineticpharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with advanced solid tumors Furthermore the safety and efficacy of SC10914 in patients with advanced solid tumors and negative expression of ATM or BRCA1 or BRCA2 mutation will be evaluated in expanded cohorts to establish the Recommended Phase 2 DoseRP2D
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None